One To Watch

Hansa Biopharma

A Sweden-headquartered specialty biopharmaceutical company developing and commercializing enzyme-based therapies, with a strategic focus on immunomodulation and enabling access to biologics and transplantation through antibody-cleaving technology. Hansa’s lead platform centers on IgG-degrading enzymes designed to rapidly and specifically remove pathogenic or treatment-limiting antibodies.

Company Overview

Hansa Biopharma develops medicines that target antibodies as a way to change disease biology and unlock treatment options. The company’s best-known approach is enzymatic IgG cleavage, intended to reduce circulating IgG levels quickly and thereby address conditions where antibodies are directly pathogenic or where pre-existing antibodies prevent the use of certain therapies.

Hansa’s development strategy has two main pillars: immunology programs aimed at antibody-driven disease and “enabling” applications where antibody removal can make otherwise inaccessible treatments possible, particularly in transplantation.

Headquarters and Global Presence

Hansa is headquartered in Lund, Sweden. The company operates across major European and North American markets through a combination of direct activities and partner-supported clinical and commercial infrastructure, aligned to its focus on specialist prescribers in transplant centers and immunology settings.

Founding and History

Hansa Biopharma originated in Sweden and has been built around antibody-cleaving enzyme technology. Over time, the company has progressed from platform development to specialist commercialization through its lead product in transplantation enabling, while advancing additional enzyme-based candidates intended to broaden both the platform’s reach and the company’s commercial footprint.

The company’s more recent profile has been shaped by efforts to expand beyond its initial transplant use case, including new development programs and broader partnering activity.

Therapy Areas and Focus

Hansa’s core focus areas are:

Transplantation, focused on desensitization to enable kidney transplantation in highly sensitized patients
Immunology, targeting antibody-mediated and immune-complex driven diseases
Enabling therapy applications where removal of IgG may unlock access to biologics or other treatments blocked by pre-existing antibodies

Technology Platforms and Modalities

Hansa’s platform is centered on enzyme-based immunomodulation, specifically targeted degradation of IgG.

Key elements include:

IgG-cleaving enzymes designed for rapid antibody removal
A platform rationale that separates antibody elimination from broader immunosuppression, aiming for a focused mechanistic intervention
Follow-on enzyme candidates and lifecycle work intended to optimize durability, dosing and expansion into additional antibody-mediated indications

Key Personnel

Søren Tulstrup, President and Chief Executive Officer
Klas Streiffert, Chief Medical Officer
Fredrik Palm, Chief Financial Officer

Strategic Partnerships

Hansa’s business model includes partnerships that support development, market access and commercialization in specialist settings. The company also positions its technology as potentially applicable across multiple external programs where antibody removal could increase patient eligibility or improve treatment feasibility, supporting collaboration structures that combine platform use with disease-area expertise.

FAQ Section

Hansa develops enzyme-based therapies that target IgG antibodies. Its strategic focus is immunomodulation through antibody removal, with near-term emphasis on transplantation enabling and longer-term expansion into additional antibody-mediated diseases.

Hansa’s lead product is an IgG-degrading enzyme therapy used to desensitize highly sensitized kidney transplant candidates. It is positioned to remove donor-specific antibodies rapidly, increasing the likelihood that a compatible transplant can proceed.

The company prioritizes transplantation and immunology. Transplantation provides a specialist commercial pathway in kidney transplant centers, while immunology programs aim to broaden the platform into diseases where antibodies drive pathology or limit response to standard therapies.

Conventional immunosuppression broadly dampens immune activity. Hansa’s approach is more targeted: it aims to remove IgG antibodies directly and quickly, potentially enabling clinical effects without relying solely on broad suppression of immune cell function.

Key watchpoints include the consistency and durability of antibody reduction, real-world transplant enablement rates, the operational fit within transplant center workflows, and reimbursement/access dynamics given the specialist, procedure-linked nature of desensitization.

For antibody-mediated diseases, the main considerations are selecting indications where rapid IgG removal is clinically meaningful, demonstrating durable benefit beyond short-term antibody reduction, and establishing safe repeat dosing strategies where needed.

The most important milestones are execution-driven: continued uptake and clinical integration of the transplantation product, advancement of immunology pipeline programs through Phase I, Phase II and Phase III, and evidence that the platform can generate repeatable value across multiple indications rather than remaining primarily a single-use-case technology.

Want to Update your Company's Profile?

More Hansa Biopharma news >